Understanding the distribution of HPV types in cervical cancer cases is crucial for evaluating the effectiveness of HPV screening and vaccination in reducing the burden of cervical cancer. Our findings demonstrated that 92.7% of the women diagnosed with cervical cancer between 1995 and 2015 in Troms and Finnmark counties tested positive for HPV in at least one test, identifying HPV 16 and 18 as the predominant types responsible for 70.8% of the cases.

Based on the genotype distribution reported from the pre-vaccine era, it was evident that the implementation of the bivalent or quadrivalent HPV vaccines could potentially prevent 76.4% of the HPV-positive cervical cancer cases, while the nonavalent HPV vaccine has the potential to improve prevention to 93.3%.

You can read the full text here: https://www.mdpi.com/2673-5261/4/3/15